New DNA sequencing facility established in China based on PacBio's SMRT sequencing platform

Oct. 29, 2014

Pacific Biosciences of California, Inc., provider of the PacBio RS II DNA Sequencing System, and Suqian Lakeside Pangu Gene Company (SLPC) announces that SLPC has established a new genomics facility dedicated to using PacBio Single Molecule, Real-Time (SMRT) Sequencing as the major sequencing platform for its translational medicine research projects.

SLPC purchased four PacBio RS II Sequencing Systems earlier this year and recently installed them at their newly dedicated facility. The company ultimately intends to focus on applications such as molecular-based approaches for early diagnosis of cancers, disease recurrence control and drug efficacy evaluation.

Ram Laxman, PhD, President & General Manager, Asia Pacific for Pacific Biosciences comments, “SLPC's investment in the PacBio RS II systems for human and other large genome sequencing follows a growing trend of researchers adopting the SMRT Sequencing technology to generate highly accurate complete genomes.”

Pacific Biosciences' SMRT Sequencing technology achieves long read lengths, high consensus accuracy, and a low degree of bias. Company representatives say these characteristics, combined with the ability to detect many types of DNA base modifications (e.g., methylation) as part of the sequencing process, make the PacBio RS II a valuable tool for many scientists studying genetic and genomic variation. Learn more about the PacBio SMRT.

Read more

ID 338444704 © Tetiana Kitura | Dreamstime.com
dreamstime_xxl_338444704
ID 52876413 © Photowitch | Dreamstime.com
dreamstime_xxl_52876413
ID 178324136 © Prostockstudio | Dreamstime.com
dreamstime_xxl_178324136